Analyst Price Targets — ATRC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 18, 2026 12:08 pm | — | UBS | $55.00 | $32.97 | TheFly | AtriCure price target lowered to $55 from $60 at UBS |
| February 18, 2026 12:02 pm | William Plovanic | Canaccord Genuity | $53.00 | $32.97 | TheFly | AtriCure price target lowered to $53 from $64 at Canaccord |
| February 18, 2026 11:09 am | — | Oppenheimer | $44.00 | $32.97 | TheFly | AtriCure downgraded to Perform from Outperform at Oppenheimer |
| October 30, 2025 10:27 am | William Plovanic | Canaccord Genuity | $64.00 | $35.44 | StreetInsider | AtriCure Inc. (ATRC) PT Raised to $64 at Canaccord Genuity |
| July 30, 2025 11:07 am | — | BTIG | $54.00 | $35.13 | TheFly | AtriCure price target raised to $54 from $52 at BTIG |
| July 31, 2024 6:57 am | Rick Wise | Stifel Nicolaus | $26.00 | $22.00 | TheFly | AtriCure price target lowered to $26 from $30 at Stifel |
| July 31, 2024 6:51 am | Matt O'Brien | Piper Sandler | $40.00 | $22.00 | TheFly | AtriCure price target lowered to $40 from $65 at Piper Sandler |
| July 31, 2024 4:58 am | Marie Thibault | BTIG | $53.00 | $22.00 | StreetInsider | AtriCure Inc. (ATRC) PT Lowered to $53 at BTIG |
| May 2, 2024 5:54 am | Mike Matson | Needham | $40.00 | $24.76 | StreetInsider | AtriCure Inc. (ATRC) PT Lowered to $40 at Needham |
| May 2, 2024 5:25 am | Marie Thibault | BTIG | $58.00 | $24.76 | StreetInsider | AtriCure Inc. (ATRC) PT Lowered to $58 at BTIG |
Latest News for ATRC
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Citizens Life Sciences Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, March…
AtriCure (NASDAQ: ATRC) reported fourth-quarter and full-year 2025 results that management said reflected accelerating growth in several core franchises, improving profitability, and progress on major clinical and product development initiatives. The company also reaffirmed its 2026 outlook for 12% to 14% revenue growth. Full-year and fourth-quarter financial results For full-year 2025, AtriCure posted worldwide…
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript
AtriCure (ATRC) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.08 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ATRC.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.